- Home
- CERS
CERS
Cerus Corporation
as 03-28-2025 4:00pm EST
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | CONCORD |
| Market Cap: | 347.3M | IPO Year: | 1997 |
| Target Price: | $3.50 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $2.54 | Next Earning Date: | 05-01-2025 |
| Revenue: | $180,270,000 | Revenue Growth: | 15.29% |
| Revenue Growth (this year): | 25.22% | Revenue Growth (next year): | 10.08% |
Stock Insider Trading Activity of Cerus Corporation (CERS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jensen Chrystal | CERS | Chief Legal Officer | Mar 13 '25 | Sell | $1.45 | 49,024 | $71,084.80 | 813,369 | |
| Greenman William Mariner | CERS | President and CEO | Mar 13 '25 | Sell | $1.45 | 193,913 | $281,173.85 | 4,238,672 | |
| Green Kevin Dennis | CERS | Chief Financial Officer | Mar 13 '25 | Sell | $1.45 | 59,887 | $86,836.15 | 912,607 | |
| Benjamin Richard J | CERS | Chief Medical Officer | Mar 13 '25 | Sell | $1.45 | 49,024 | $71,084.80 | 685,775 | |
| Jayaraman Vivek K | CERS | Chief Operating Officer | Mar 13 '25 | Sell | $1.45 | 75,989 | $110,184.05 | 1,431,326 | |
| Jensen Chrystal | CERS | Chief Legal Officer | Mar 6 '25 | Sell | $1.50 | 27,457 | $41,130.59 | 813,369 | |
| Greenman William Mariner | CERS | President and CEO | Mar 6 '25 | Sell | $1.50 | 60,984 | $91,354.03 | 4,238,672 | |
| Green Kevin Dennis | CERS | Chief Financial Officer | Mar 6 '25 | Sell | $1.50 | 31,148 | $46,659.70 | 912,607 | |
| Benjamin Richard J | CERS | Chief Medical Officer | Mar 6 '25 | Sell | $1.50 | 26,139 | $39,156.22 | 685,775 | |
| Jayaraman Vivek K | CERS | Chief Operating Officer | Mar 6 '25 | Sell | $1.50 | 33,999 | $50,930.50 | 1,431,326 |
Latest Cerus Corporation News
CERS Breaking Stock News: Dive into CERS Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Cerus Leads Our Selection Of 3 Promising Penny Stocks
Simply Wall St.
8 days ago
Are Investors Undervaluing Cerus Corporation (NASDAQ:CERS) By 49%?
Medical Device Network
23 days ago
Cerus secures CE mark approval for LED-based illumination device
MT Newswires
24 days ago
Cerus Receives CE Mark for INT200 Illumination Device
Business Wire
24 days ago
Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)
Simply Wall St.
a month ago
Cerus Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
a month ago
Cerus Corp (CERS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow
Associated Press Finance
a month ago
Cerus: Q4 Earnings Snapshot
Compare CERS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CERS Cerus Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.